Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D ( Factor D ), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria [1] [2].
In Vitro, Zaltenibart can safely and effectively significantly increase and maintain hemoglobin levels while controlling hemolysis[1].
References:
[1]. Griffin M, et al. Monotherapy treatment with Zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to Ravulizumab: Interim results from a phase 2 proof-of-concept study. Blood. 2024 Nov 5;144:4072.
[2]. Kelly RJ, et al. Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition. Drugs. 2025;85(11):1413-1428.
In Vitro, Zaltenibart can safely and effectively significantly increase and maintain hemoglobin levels while controlling hemolysis[1].
References:
[1]. Griffin M, et al. Monotherapy treatment with Zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to Ravulizumab: Interim results from a phase 2 proof-of-concept study. Blood. 2024 Nov 5;144:4072.
[2]. Kelly RJ, et al. Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition. Drugs. 2025;85(11):1413-1428.